Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaiser, M
Right arrow Articles by Heider, U
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaiser, M
Right arrow Articles by Heider, U
Haematologica, Vol 91, Issue 2, 248-251
Copyright © 2006 by Ferrata Storti Foundation

Journal Article

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma

M Kaiser, I Zavrski, J Sterz, C Jakob, C Fleissner, PM Kloetzel, O Sezer, and U Heider

Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, 10117, Berlin, Germany.

The aim of this study was to evaluate the effects of valproic acid (VPA), as a histone deacetylase inhibitor, on myeloma cell lines and on sorted human bone marrow multiple myeloma cells. VPA induced accumulation of acetylated histones, potently inhibited proliferation in a dose-dependent manner and induced apoptosis in all myeloma cell lines tested as well as in sorted primary multiple myeloma cells. Cell cycle analysis indicated an arrest in G0/1 phase in response to VPA. Accumulation of p21 and reduced levels of cyclin D1 were detected. The production of vascular endothelial growth factor was significantly inhibited by VPA. These results provide the framework for clinical trials.


This article has been cited by other articles:


Home page
 The OncologistHome page
D. Y. Greenblatt, A. M. Vaccaro, R. Jaskula-Sztul, L. Ning, M. Haymart, M. Kunnimalaiyaan, and H. Chen
Valproic Acid Activates Notch-1 Signaling and Regulates the Neuroendocrine Phenotype in Carcinoid Cancer Cells
Oncologist, August 1, 2007; 12(8): 942 - 951.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Verhelle, L. G. Corral, K. Wong, J. H. Mueller, L. Moutouh-de Parseval, K. Jensen-Pergakes, P. H. Schafer, R. Chen, E. Glezer, G. D. Ferguson, et al.
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
Cancer Res., January 15, 2007; 67(2): 746 - 755.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
C.-L. Chen, J. Sung, M. Cohen, W. H. Chowdhury, M. D. Sachs, Y. Li, Y. Lakshmanan, B. Y. M. Yung, S. E. Lupold, and R. Rodriguez
Valproic Acid Inhibits Invasiveness in Bladder Cancer but Not in Prostate Cancer Cells
J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 533 - 542.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W.-h. Feng and S. C. Kenney
Valproic Acid Enhances the Efficacy of Chemotherapy in EBV-Positive Tumors by Increasing Lytic Viral Gene Expression.
Cancer Res., September 1, 2006; 66(17): 8762 - 8769.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.